Thursday 30 October 2014

Membrane Technology Market Growth 2014 - 2019

The global membrane technology market for pharmaceutical, biopharma and life sciences is estimated at USD 6,461.3 million in 2013 and is expected to grow at a CAGR of 9.1% from 2014 to 2019, to reach an estimated value of USD 10,886 million in 2019.

Browse Global Membrane Technology Market Report with Full TOC at http://www.transparencymarketresearch.com/membrane-technology-market.html

The membrane technology market is witnessing significant growth due to increasing research and development and production in pharmaceutical, biopharmaceutical and life sciences industries. Thus, rise in pharmaceutical production and increasing number of membrane technology applications worldwide are driving the growth of membrane technology in pharmaceutical, biopharmaceutical and life sciences industries.

Additionally, stringent regulations and usage of single-use disposable technique are playing a major role in growth of the membrane technology market. Presence of various filtration techniques such as ultrafiltration, nanofiltration and microfiltration under membrane technology has increased its acceptance in pharmaceutical, biopharmaceutical and life science industries for separation and purification of components and biomolecules, over conventional techniques. However, the market faces some restraints such as effects of membrane fouling, high operational and investment cost and limitation of membrane materials. As a result, the market is expected to grow at a CAGR of about 9.1% during 2014-2019.

Globally, North America is the largest market for membrane technology in pharmaceutical, biopharmaceutical and life sciences industries. The U.S. is the world's largest market for pharmaceutical and biopharmaceutical products. According to the European Federation of Pharmaceutical Industries and Associations, North America accounted for about 41% of global pharmaceutical sales in 2012. Pharmaceutical and biopharmaceutical firms in the U.S. conduct 80% of research and development of innovative medicines in the world. The pharmaceutical market in the U.S. is highly regulated by the Food and Drug Administration (FDA).


In Europe, membrane technology is a rapidly growing sector with many associations, organizations and societies actively involved in expansion and implementation of this technology in various industries including pharmaceutical, biopharmaceutical and life sciences. Organizations in Europe such as the European Desalination Society (EDS), and European Membrane House (EMH) promote membrane technology usage in universities, companies, research institutes and government agencies.

However, Asia is the fastest growing region in the membrane technology market due to continuous development in pharmaceutical and biopharmaceutical industries. The region is witnessing double-digit growth (average annual growth rate of 13%) in pharmaceutical and biopharmaceutical industries due to a large population base, increasing healthcare awareness, rising incidence of chronic diseases and higher government healthcare spending.

GE Healthcare and 3M Healthcare are the leading players in the global market of membrane technology in pharmaceutical, biopharma and life sciences. Other major players of the membrane technology market include Sartorius, Merck Millipore, Koch Membrane System, Novasep and others.

The global market of membrane technology in pharmaceutical, biopharma and life sciences is segmented as follows:

Membrane Technology Market, By Technology
Ultrafiltration
Microfiltration
Nanofiltration
Chromatography

Membrane Technology Market, by Geography

North America
U.S.

Europe
Switzerland
Germany
Italy
U.K.
Ireland
France

Asia
China
India
Japan
Malaysia
Singapore
Rest of the World (RoW)

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

Wednesday 29 October 2014

Meningococcal Vaccines Market Share 2013 - 2019:Transparency Market Research

Global meningococcal vaccines market has the potential of growing at a CAGR of 14.9% during 2013 and 2019. Growing at this pace, this market that valued US$1.5 billion in 2012 could achieve a net worth of US$3.7 billion by 2019.

Browse Meningococcal Vaccines Market Report With Full TOC http://www.transparencymarketresearch.com/meningococcal-vaccines-market.html

Various strains of meningococcal bacteria cause serious infection to the thin lining surrounding the brain and spinal cord. The infection results in severe brain damage and can be fatal in 50% cases if left untreated. The high fatality rate of meningococcal disease is generally considered as a medical emergency. This is why, federal governments of various countries are actively involved in efforts for spreading awareness about the severity of the condition. Many government bodies are also involved in the research, development, and also the distribution of meningococcal vaccines regionally.
Transparency Market Research’s report on the global meningococcal vaccines market presents an all-inclusive overview of the market and its various segments.
The report mainly focuses on major market segments based on the types of vaccines available in the meningococcal vaccine market, such as Polysaccharide Vaccines, Conjugate Vaccines, Combination Vaccines, and the vaccines in pipeline. The product types are further segmented according to the brands that feature them. An overview of geographically specific active regional markets is also included in the report.
Conjugates are expected to lead the global meningococcal vaccines market in the future. By observing growth at a CAGR of 12.9%, this product segment could amass net worth of nearly US$2.5 billion by 2019. Amongst the various meningococcal vaccines in pipeline currently, Novartis’s Bexsero is expected to gain market shares at the fastest pace, an expected 24.7%, during the forecast period.


The Department of Health, UK, states that Baxsero will be the first vaccine for serogroup B in the meningococcal vaccines market after its launch in the second quarter of 2014. Pfizer’s MnB rLP2086 is another potential future vaccine that is currently in its third phase of trial. The launch of this vaccine, which has received a Breakthrough Therapy status from the U.S. FDA, is expected to change the complete outlook of this market by intensifying competition.


Geographically, North America was the leading shareholder of the global meningococcal vaccines market in 2011 due to government led immunization programs and favorable research and development initiatives undertaken by major drug companies in this region. Also, every year nearly 1,000 to 2,600 people in the U.S. contract meningitis from various strains of the bacteria. However, vaccines for only the serotypes A, C, Y, and W-135 are available in the U.S. market.


Regional market of Asia Pacific is expected to grow at the fastest pace in the global meningococcal vaccines market, at an estimated CAGR of 17.1%, by the end of 2019. Major drivers of growth in these regional markets are the low manufacturing cost of vaccines, and transfer of novel manufacturing technologies from developed countries to these regions.


About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research


Elaborated by Transparency Market Research is expected to be worth USD 20.8 billion in 2012 and is further expected to reach USD 29.5 billion in 2017, growing at a CAGR of 7.3% from 2012 to 2017.

Nutraceutical ingredients are fundamental elements needed for various health purposes, especially to prevent chronic diseases that may occur to a human due to nutrient deficiency in the body. Nutraceutical market is considered to be the largest body building segment estimated at USD 9.5 billion in 2012, and further expected to maintain its global growth and lead position in terms of revenue until 2017.

Browse Full Nutraceutical Ingredients Market Research Report: http://www.transparencymarketresearch.com/nutraceutical-ingredients-market.html

This market is one of the present-day emerging sectors in the world. It includes aspects such as dietary supplements, processors, raw material suppliers, end-use consumers, and product manufacturers. It also has products including functional food, beverages, personal care, and animal nutrition. The major drivers of the nutraceutical ingredients market include elements such as probiotics, peptides & proteins, phytochemicals & plant extracts, prebiotics, fibers & specialty carbohydrates, amino acids, omega 3 & structured lipids, minerals, vitamins, carotenoids & antioxidants. All these ingredients are acquired from different suppliers, plant sources, poultry farms, and are further served to multiple outlets in the form of beverages, functional food, personal care products and supplements to consumers across the globe. It is also due to specialty fibers and carbohydrates being the most widely used ingredients, plant extracts and phytochemicals are expected to witness a rise of promising growth within this market in the near future.

The primary growth of the nutraceutical ingredients market is due to the reliability and awareness of the nutraceutical products and the ever-increasing customer base worldwide. Nonetheless, the nutraceutical ingredients market and product market are akin to one another. Shifts in either of the market will involuntary cause a direct impact on the other. Certainly, due to a rapid growth in consumption of nutraceutical ingredients and products worldwide, several developing economies and regions have boosted the growth of nutraceutical ingredient market today.


The world has witnessed a rising economic prosperity of this market in emerging nations such as China, India, Brazil, Poland, South Korea, Mexico, South Africa, and Russia. However, the Asia-Pacific of all the regions is expected to enjoy 37.5% of the total revenue share in this market in 2017 which is then succeeded by the growth seen in North America.

Browse the full Press Release of Nutraceutical Ingredient Market: http://www.transparencymarketresearch.com/pressrelease/nutraceutical-ingredients-market.htm

The nutraceutical ingredient market is becoming popular and getting a drive ahead in various economic nations due to its wide served opportunities. With consumers flocking towards healthy diet plans, healthy nutrients regime and changing lifestyles, the worldwide markets for Nutraceutical Ingredients in USD million is popular due to segments such as controlling diabetes, body building, pain relief, and weight control. The body building market was followed by weight control in 2011; similarly, the controlling diabetes sect had showed 16.5% revenue share in 2011, becoming the third largest segment in the world.

According to the industry best market research reports forecast provided for the period 2012 through 2017, the comprehensive analytics of this market is geographically noticed for locales like Western Europe, North America, Asia-Pacific, Eastern Europe, Latin America, and MEA. Especially, the Asia-Pacific and North America nutraceutical ingredients market is expected to hold a market share of 30.4% and 39.2% respectively in 2017. In addition, the dietary supplement market will be the rapidly growing market for the forecast period 2012 to 2017. It will provide health benefits to the body and help in healing and prevention of diseases.


About Us:

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:
Sheela AK
State Tower, 90 State Street,
Suite 700, Albany NY - 12207
USA/Canada Toll Free: 866-552-3453


Tuesday 28 October 2014

Erectile Dysfunction Drugs Market Forecast 2013 - 2019:Transparency Market Research

The global erectile dysfunction drugs market was worth $4.3 billion in 2012. It is expected to decline at an aggregate rate of 4.5% between 2013 and 2019, which means the market will be valued at $3.4 billion in 2019.

Browse the full report with complete TOC at Erectile Dysfunction Drugs Market http://www.transparencymarketresearch.com/erectile-dysfunction-drugs.html

All facts and figures have be provided through a research report titled “Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019”, published by Transparency Market Research.
The report showed that Viagra (sildenafil citrate) by Pfizer held 45% of the global erectile dysfunction drugs market in 2012. Its majority hold over the market is predicted to decline after patent exclusivity rights expire in 2013 in Europe and other countries. Cialis (tadalafil) held the second-largest market share with $1.9 billion in 2012. Its patent exclusivity will reportedly expire in 2017, supplementing the decline of the erectile dysfunction drugs market by 2019. The same is to be expected from Levitra/Staxyn (Vardenafil) by Bayer, whose patent exclusivity is set to expire in 2018. The report explains that once the patents expire, the market will be flooded with competitive generic drugs with similar chemical compositions, reducing the revenue generated by the major players in the market.


Factors that might improve the growth of the erectile dysfunction drugs market are the approval of the new promising drugs Zydena (udenafil) and Stendra/Spedra (avanafil) in mid 2014.
The report categorized the global erectile dysfunction market according to the product brands or pipeline analysis. By products, the report investigates Viagra, Cialis, Levitra/Staxyn, MUSE, Zydena, Mvix, and Helleva. By pipeline analysis, the report identifies Vitaros, Uprima, Gene therapy, Melanocortin Activators, and Topiglan.

By geography, the research report identifies the regions of North America, Europe, Asia-Pacific, and Rest of the World. The North American region dominated the global erectile dysfunction drug market in revenue created. It is expected to maintain its dominance throughout the forecast period.
The key players explained in the report are Pfizer, GlaxoSmithKline, Bayer, Dong-A Pharmaceutical Corporation Limited, Eli Lilly And Company, Cristalia Produtos Quimicos Farmaceuticos Ltda., Vivus Incorporated, S.K. Chemicals Corporation Limited, Meda Pharmaceuticals, and Apricus Biosciences, Incorporated.


Erectile dysfunction is a male inability to generate and/or maintain penile erection, for the sake of a fully successful sexual intercourse. It primarily affects men above the age of 40. Typical causes of erectile dysfunction are diabetes and hypertension, along with a host of common habits attributed to a sedentary lifestyle, obesity, excessive consumption of alcohol, smoking, use of recreational drugs, and use of anti-depressants.

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA/Canada Toll Free: 866-552-3453

Monday 27 October 2014

Enteric Disease Testing Market Growth 2013 - 2019

The global enteric disease testing market is estimated to be worth $3,643.4 million by the end of 2019. The report, titled ‘Enteric Disease Testing Market (Amebiasis, C.difficile Infection, Campylobacteriosis, Cholera, Cryptosporidiosis, E.coli Infection, Giardiasis, H.pylori Infection, Norovirus Infection, Rotavirus Infection, Salmonellosis and Shigellosis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,’ is now available for sale on the company’s website.

Browse the full report with complete TOC at Enteric Disease Testing Market http://www.transparencymarketresearch.com/enteric-disease-testing-market.html

This market research report has given a detailed analysis of the global enteric disease testing market which takes into account enteric diseases caused due to twelve major types of infections which include Amebiasis, Campylobacteriosis, Giardiasis, Salmonellosis, Norovirus infection, Cryptosporidiosis and Clostridium difficile mediated infection.

Gastrointestinal infections caused by viruses, bacteria and parasites are known as enteric diseases. These aforementioned microbes generally enter the human body through the mouth or the intestinal systems. These diseases may exhibit mild or severe symptoms which include abdominal pains, fever, stool consisting of pus or blood, bloody diarrhea and in some cases weight loss. Sometimes, these diseases may not even show any symptoms. The intensity and the severity of the disease determines the period of incubation which can vary from just a couple of days to several weeks. For effective cure, these diseases should ideally be diagnosed at an early stage.


This report consists of a comprehensive analysis of the global enteric disease testing market which has been segmented on the basis of the types of enteric diseases and the types of tests incorporated for identification of the diseases which include rapid and conventional diagnostic kits. Rapid test cassette and rapid dipstick are the two main types of rapid tests and technologies used for diagnosis.

The reasons responsible for the significant shift to rapid tests from culture tests have also been explained in this report. These factors pertain to the problems associated with culture tests that involve high costs and it being labor intensive. Furthermore, culture tests require highly skilled personnel and a sophisticated laboratory set up for effective diagnosis.
The extensively used enteric disease testing techniques include rapid dipstick test, and molecular diagnostic based tests like polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA).


According to this market research report, the most lucrative market for enteric disease testing is the Asia Pacific which accounts for more than half the world’s population. Moreover, this region is characterized by a major section of the population being infected by enteric microbes as a consequence of unhygienic conditions and improper sanitation facilities. The enteric disease market in this region is driven by factors like high incidence of enteric diseases, increasing awareness and greater expenditure on healthcare by economies like China and India.


The Asia Pacific will witness a growth in the enteric disease market for rapid dipstick test kits in the forthcoming years. Rapid dipstick test kits are popular because these are not only cost effective but they also enable quick results. And economically stable countries like New Zealand, Japan and Australia will witness high growth in the market for molecular diagnostic based testing techniques.

Some of the prominent players in the global enteric disease testing market covered in this market research report include Trinity Biotech, Alere, Inc., Quest Diagnostics, Becton Dickinson & Company, Meridian Bioscience, Inc., Biomerica, Inc., Diasorin, Biomerieux, Coris Bioconcept, Bio-Rad and Cepheid.

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA/Canada Toll Free: 866-552-3453


Biological Drugs Market 2014 - 2020

The biological drugs market encompasses a class of medicine that is developed through genetic modification of monoclonal antibodies. Monoclonal antibodies naturally inhabit the human immune system and help the body in fighting from a variety of diseases.

Browse Full Global Biological Drugs Market Market Research Report With Complete TOC @ http://www.transparencymarketresearch.com/biological-drugs-market.html

When these antibodies are genetically modified, they can be used to treat specific diseases. Biological drugs differ from normal prescription drugs in the sense that they can produce almost “pinpoint” accurate results and have the capability of tracking down the sites or cells that need to be treated. In theoretical terms, biological drugs are capable of finding diseases cells in such an effective manner that they make the treatment entirely safe and effective, with fewer side effects. Biological drugs are in many ways the answer to the key concern of effective and safe healthcare.

In actual use too, biological drugs have been found to be very effective against a number of chronic diseases. Often termed as “future drugs”, the market for biological drugs has been observing growth at an immense pace and is soon expected to surpass markets of normal prescription drugs for chronic conditions.


Market Statistics

The global market of these “medicines-of-the-future” is witnessing growth at a significant pace. Three factors are majorly responsible for this – rising percentage of world’s ageing population, rising prevalence of a number of chronic diseases, and growing awareness about benefits of biological drugs.

In 2009, the global biological drugs market grew at a CAGR of 9.6% and expanded from US$1, 01,656.5 million in 2009 to US$1,46,548.2 million in 2013.

High success rates of biological drugs in effectively curing many chronic diseases such as arthritis, asthma, diabetes, and cancer in the past few years have prompted government associations in promoting usage of biological drugs over normal prescription drugs. Moreover, the research and development on the field of biological drugs presents immense growth potential for this market.

All these factors will help the market in achieving market value of US$161,056.5 million in 2014. By the end of 2020, this market could amass net worth of US$287,139.7 million.
Benefits

Biological drugs have shown to have better health effects in the long run, with very few side-effects. Studies say that these factors lead to quick recovery and less additional treatment due to the lack of many side-effects. To the end user, the most attractive benefit of using biological drugs is the improvement in quality of life after being treated with these drugs.
Currently, there are only a few FDA-approved biological drugs in the market. The ones in market are formulated for chronic conditions such as asthma, diabetes, cancer, irritable bowel syndrome, etc. However, the realization of potential benefits of biological drugs has put them on fast track approval from the FDA. The development of biological drugs is occurring at such a rate that many of the newly introduced biological drugs have gained FDA approval within only a few days.


A major concern with the growth of biological drugs market is the high cost of these medicines. Biological drugs are currently priced at higher rates than normal prescription drugs. However, bulk production of biological drugs in the future will allow reduction in prices.
Market Segmentation

The regional market of North America currently leads the global biological drugs market. The high rate of awareness amongst end-users in this region is the major reason behind stronghold of the biological drugs market in the region. The biological drugs market is also flourishing in Europe due to increased usage of these medicines for chronic conditions such as cancer, diabetes, and inflammatory diseases.

The low cost of manufacturing in Asia-Pacific is attracting investments from global biological drugs manufacturers in these regions, supporting to further growth of the biological drugs market. Moreover, central governments in Asian countries are also supporting growth of the market by increasing investments in biotech companies for research and development of novel biological drug formulations.

Browse All Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Ms. Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453


Monday 20 October 2014

Hospital Pharmaceuticals Market Growth 2014 - 2020

Pharmaceutical drug sales are sold through various channels such as retail, mail orders, clinics and hospitals. Retail channel generate sales followed by mail orders, and collectively account for more than 50% of the pharmaceutical drugs sales. Hospital however account for a smaller share of about 8.6% of the total sales. This report exclusively studies the market for pharmaceutical drugs that are sold or delivered to patients in hospital settings.

Browse the full Hospital Pharmaceuticals Market Report at http://www.transparencymarketresearch.com/hospital-pharmaceuticals-market.html

Global hospital pharmaceutical drugs market is segmented according to major therapeutic areas, which include: cardiology, oncology, nephrology and urology, neurology, pain and infection. Market for these major therapeutic areas has been further assessed according to drug classes. Cardiology segment is further divided into diuretic drugs, calcium channel inhibitors, anti-cholinergic agents, anti-arrhythmic agents, anti-adrenergic agents, and others (ACE inhibitors, angiotensin receptor blockers, anticoagulants). Oncology segment is further segmented into immunomodulating agents, alkylating agents, anti-metabolites, hormonal agents, and miscellaneous drugs. Nephrology and urology segment is further divided into diuretic drugs, anti-hypertensive agents, phosphate binders, anti-cholinergic agents and 5-alpha-reductase inhibitors. Neurology segment is divided into anti-anxiety, anti-migraine, anti-depressant and anti-psychotic drugs. Market for pain management drugs has been divided into anti-convulsant drugs, anesthetics, nonsteroidal anti-inflammatory drugs (NSAID), opioids, and non-narcotic analgesic drugs. Similarly anti-infective drugs market has been segmented into anti-bacterial drugs, anti-viral drugs, anti-fungal drugs and anti-parasite drugs. The report also provides a detailed list of potential phase III candidates for each of the therapeutic areas.

The market has been further studied from the point of view of major diseases in these therapeutic areas. Thus the cardiology market has been studied considering coronary heart diseases, stroke, high blood pressure (hypertension), heart failure and other cardiovascular diseases. Oncology drugs market has been studied for lung cancer, breast cancer, colorectal cancer, prostate cancer, and others. Nephrology and urology drugs market is studied for acute kidney failure, chronic kidney diseases, glomerular diseases, diabetes and other diseases. Neurology market has been studied for epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, stroke and other diseases.


Market for pain has been studied for neuropathic pain, fibromyalgia, osteoarthritis, rheumatoid arthritis, cancer pain and others. The infection market is studied for major infectious disease such as tuberculosis, pneumonia, hepatitis A, hepatitis B, Candida infections, fungal meningitis, shigellosis, amoebiasis and other infections. The report also provides insights for various branded and blockbuster drugs under various therapeutic drug class along with other details such as manufacturer, approval date and the patent expiry.


The Global Hospital Pharmaceuticals Market is segmented into the following categories:

Cardiology
Anti-Adrenergic Drugs
Calcium Channel Blockers
Diuretic Drugs
Anti-Arrhythmic Drugs
Others


Oncology
Alkylating Agents
Anti-Metabolites
Hormonal Agents
Immunomodulating Agents
Miscellaneous Drugs

Nephrology and Urology
Diuretic Agents
Anti-Hypertensive Agents
Phosphate Binders
Anticholinergic Drugs
5-Alpha Reductase Inhibitors

Neurology
Anti-Anxiety Agents
Detail2Anti-Migraine Drugs
Antidepressant Drugs
Anti-Psychotic Drugs

Pain
Anticonvulsant Drugs
Anesthetic Drugs
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Opioids
Non-Narcotics Analgesic Drugs

Infection
Antibacterial Drugs
Antiviral Drugs
Antifungal Drugs
Antiparasite Drugs

Global Hospital Pharmaceuticals Market, by Major Indications

Cardiology
Coronary Heart Diseases
Stroke
High Blood Pressure
Heart Failure
Others

Oncology
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Others

Nephrology and Urology
Acute Kidney Failure
Chronic Kidney Diseases
Glomerular Diseases
Diabetes
Others

Neurology
Epilepsy
Alzheimer;s Disease
Parkinson;s Disease
Multiple Sclerosis
Others

Pain
Neuropathic Pain
Fibromyalgia
Osteoarthritis
Rheumatoid Arthritis
Cancer Pain

Infection
Detail1Tuberculosis
Pneumonia
Hepatitis A
Hepatitis B
Candida Infection
Fungal Meningitis
Shigellosis
Amoebiasis
Other

Global Hospital Pharmaceuticals Market, by Geography
North America
Europe
Asia Pacific
Rest of the World (RoW)


About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Ms. Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

Thursday 16 October 2014

Ophthalmic Drugs Market Growth 2013 - 2018

The global ophthalmic drugs market was valued at USD 16 billion in 2012 and is expected to grow at a CAGR of 5.2% from 2013 to 2018, to reach an estimated value of USD 21.6 billion in 2018.

Browse the full Ophthalmic Drugs Market Report with TOC at http://www.transparencymarketresearch.com/ophthalmic-drugs-market.html

Globally, the ophthalmic drugs market is witnessing significant growth due to increasing prevalence of eye disorders such as diabetic retinopathy and macular degeneration. As a result, this market is expected to grow at a CAGR of about 5.2% during 2013 - 2018.

Some of the key driving factors for the ophthalmic drugs market are rising prevalence of global aging population, increasing government initiatives towards healthcare infrastructure in developing countries (such as India and China), technological changes in drug delivery technique, and increasing prevalence of lifestyle associated diseases. However, the market faces some restraints such as lack of awareness among people regarding eye disorders, drying pipeline of ophthalmic drugs, patent expiration of blockbuster ophthalmic drugs and absence of health insurance in developing countries.

North America, including the US has the largest ophthalmic drugs market. Asia is the fastest growing ophthalmic drugs market. Some of the fastest growing markets for ophthalmic drugs are China, India, other countries in South East Asia and the Eastern Mediterranean. As per WHO estimates in 2010, in the next nine years, the number of blind people aged 50 years and above will grow in these regions, thereby increasing the demand for ophthalmic drugs. On the other hand, in developed regions such as North America and Western Europe, rising efforts towards prevention of blindness among the aging population has emerged as a key driver for the market.


Glaucoma has the largest market share in the ophthalmic drugs market and it is expected to grow at a CAGR of about 4.2% during 2013 - 2018. Various ophthalmic drug companies are increasing their focus on combination therapy, which involves use of more than one medication for specific retinal disorders. Most of these combination therapies are used as first line treatment in patients with high level of intraocular pressure. Combination therapy has various advantages over traditional medication such as reduced frequency of eye drop application, improved patient compliance and efficacy.


Novartis (Alcon) is the leading player in the global ophthalmic drugs market while other major players include Allergan, Santen, Pfizer, Merck and Roche.


The global ophthalmic drugs market is segmented as follows:

Ophthalmic Drugs Market, By Treatment Drugs

Dry Eye Drugs
Retinal Drugs
Anti-inflammatory/allergy/infective Drugs
Anti-glaucoma Drugs

Ophthalmic Drugs Market, By Types
Prescription Drugs
OTC Drugs

Ophthalmic Drugs Market, by Geography
North America
US
Europe
Germany
UK
France
Asia Pacific
Japan
China
India
Rest of the World (RoW)

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com